Developer of immuno-oncology therapies intended to respond to the urgent needs of cancer treatment. The company's therapies develop checkpoint blockers on the innate immunity STING pathway, that enhance the killing power of tumor-infiltrating lymphocytes and produce durable responses in a small fraction of terminal melanoma patients, enabling patients to get access to a wide range of cancer treatments.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Early Stage VC (Series A) | 22-Jun-2021 | $9.7M | 000.00 | 000.00 | Completed | Pre-Clinical Trials |
1. Seed Round | 000 | 000 | 0000 | Completed |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | 00,000,000 | 00.000000 | 00.0 | 00.0 | 00 | 00.0 | 00.000 | |
Seed | 0,000,000 | 00.000000 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
Name | Representing | Role | Since |
---|---|---|---|
Chih-Ping Liu Ph.D | Angarus Therapeutics | Founder & Chairman | 000 0000 |
Jean Liu JD | Self | Board Member | 000 0000 |
Nigel Ray | Angarus Therapeutics | Chief Executive Officer, President & Board Member | 000 0000 |
Peder Jensen MD | Angarus Therapeutics | Board Member | 000 0000 |
Peter Langecker Ph.D | Self | Board Member | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Evolution VC Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Foothill Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Sixth Borough Capital Management | PE/Buyout | Minority | 000 0000 | 000000 0 |